Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms.

Publication Type:

Journal Article


Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 28, Issue 18, p.3023-7 (2010)


2010, Angiogenesis Inhibitors, Center-Authored Paper, Follow-Up Studies, Humans, Multiple Myeloma, Neoplasm Recurrence, Local, Public Health Sciences Division, Remission Induction, Survival Rate, Thalidomide, Time Factors, Treatment Outcome


In Total Therapy 2, after randomly assigning 323 patients with myeloma to thalidomide and 345 to a control arm, no difference was observed in overall survival, with a median follow-up of 42 months, although at 72 months, survival was superior on the thalidomide arm in the one third exhibiting cytogenetic abnormalities (CA). After further follow-up of 87 months, we examined, in reiterative analyses, the effect of increasing time intervals on clinical outcomes relevant to baseline prognostic variables and treatment randomization.